{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:00:45Z","timestamp":1790190045904,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A human cytomegalovirus (CMV) vaccine to prevent congenital disease is a public health priority. We previously demonstrated that vaccine-elicited rhesus CMV (RhCMV) neutralizing titers and T-cell responses comparable to natural infection failed to protect from RhCMV infection after experimental oral challenge. Consequently, we established a natural transmission model in which newborn rhesus macaques are cohoused with their RhCMV-positive mothers and immunized 5 times between 0 and 24 months with glycoprotein B (gB), pentamer, pp65, and in 1 group viral interleukin 10. While no significant differences were observed in infection rate between the vaccine and placebo groups at 40 weeks after birth, partial protection was observed at week 52 (83.3% infection in placebo, 42.1%\u201350% in vaccine recipients). Within 14 weeks of juvenile macaques transfer to group housing, all shed RhCMV. These results suggest that the neonatal RhCMV natural transmission model may recapitulate observations in humans immunized with recombinant gB and can be a useful tool for evaluating CMV vaccine candidates.<\/jats:p>","DOI":"10.1093\/infdis\/jiag170","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:42:04Z","timestamp":1774010524000},"page":"e583-e594","source":"Crossref","is-referenced-by-count":1,"title":["Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus Vaccine Development"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-2479","authenticated-orcid":false,"given":"Teeba","family":"Jihad","sequence":"first","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan S","family":"Chi","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"He","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok","family":"Lee","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Needle","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Loschko","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Goymer","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7279-2450","authenticated-orcid":false,"given":"Helen","family":"Wang","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Boigard","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8086-9311","authenticated-orcid":false,"given":"Camille","family":"Robertson","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Obregon","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey","family":"Wilson","sequence":"additional","affiliation":[{"name":"Pfizer Research Biostatistics , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-9377","authenticated-orcid":false,"given":"Isis","family":"Kanevsky","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8298-5779","authenticated-orcid":false,"given":"Paul","family":"Liberator","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury V","family":"Matsuka","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U","family":"Jansen","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhen","family":"Yang","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-6360","authenticated-orcid":false,"given":"Philip R","family":"Dormitzer","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena A","family":"Swanson","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1370-5234","authenticated-orcid":false,"given":"Nicholas J","family":"Buchkovich","sequence":"additional","affiliation":[{"name":"Vaccines, Pfizer Research and Development, Pfizer, Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026092314175747200_jiag170-B1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass","year":"1999","journal-title":"J Infect Dis"},{"key":"2026092314175747200_jiag170-B2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"2026092314175747200_jiag170-B3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12985-020-01390-2","article-title":"Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes","volume":"17","author":"Shibamura","year":"2020","journal-title":"Virol J"},{"key":"2026092314175747200_jiag170-B4","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.1128\/JVI.01325-15","article-title":"Human cytomegalovirus gH\/gL\/gO promotes the fusion step of entry into all cell types, whereas gH\/gL\/UL128-131 broadens virus tropism through a distinct mechanism","volume":"89","author":"Zhou","year":"2015","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/vim.1996.9.211","article-title":"Transplacentally acquired antiviral antibodies and outcome in congenital human cytomegalovirus infection","volume":"9","author":"Boppana","year":"1996","journal-title":"Viral Immunol"},{"key":"2026092314175747200_jiag170-B6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/315445","article-title":"Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs","volume":"181","author":"Gyulai","year":"2000","journal-title":"J Infect Dis"},{"key":"2026092314175747200_jiag170-B7","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/jvi.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/vaccines1040398","article-title":"Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial","volume":"1","author":"Smith","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"2026092314175747200_jiag170-B9","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1128\/JVI.01708-06","article-title":"Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques","volume":"81","author":"Yue","year":"2007","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B10","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1073\/pnas.97.4.1695","article-title":"Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10)","volume":"97","author":"Kotenko","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092314175747200_jiag170-B11","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1182\/blood-2008-12-197111","article-title":"The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency","volume":"114","author":"Cheung","year":"2009","journal-title":"Blood"},{"key":"2026092314175747200_jiag170-B12","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1128\/JVI.02173-07","article-title":"Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection","volume":"82","author":"Jenkins","year":"2008","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B13","doi-asserted-by":"crossref","first-page":"e28127","DOI":"10.1371\/journal.pone.0028127","article-title":"Design and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirus","volume":"6","author":"Logsdon","year":"2011","journal-title":"PLoS One"},{"key":"2026092314175747200_jiag170-B14","doi-asserted-by":"crossref","first-page":"13036","DOI":"10.1073\/pnas.1903317116","article-title":"Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity","volume":"116","author":"Deere","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092314175747200_jiag170-B15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/infdis\/jiac129","article-title":"Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T-cell responses","volume":"226","author":"Li","year":"2022","journal-title":"J Infect Dis"},{"key":"2026092314175747200_jiag170-B16","doi-asserted-by":"crossref","first-page":"e0206330","DOI":"10.1371\/journal.pone.0206330","article-title":"Natural history of postnatal rhesus cytomegalovirus shedding by dams and acquisition by infant rhesus monkeys","volume":"13","author":"Kaur","year":"2018","journal-title":"PLoS One"},{"key":"2026092314175747200_jiag170-B17","doi-asserted-by":"crossref","first-page":"6620","DOI":"10.1128\/JVI.77.12.6620-6636.2003","article-title":"Complete sequence and genomic analysis of rhesus cytomegalovirus","volume":"77","author":"Hansen","year":"2003","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B18","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1128\/JVI.80.8.4179-4182.2006","article-title":"Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus","volume":"80","author":"Rivailler","year":"2006","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B19","doi-asserted-by":"crossref","first-page":"e0165321","DOI":"10.1128\/jvi.01653-21","article-title":"Pathogenesis of wild-type-like rhesus cytomegalovirus strains following oral exposure of immune-competent rhesus macaques","volume":"96","author":"Yue","year":"2022","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00430-021-00722-5","article-title":"Human cytomegalovirus multiple-strain infections and viral population diversity in haematopoietic stem cell transplant recipients analysed by high-throughput sequencing","volume":"210","author":"Dhingra","year":"2021","journal-title":"Med Microbiol Immunol"},{"key":"2026092314175747200_jiag170-B21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1086\/649903","article-title":"Cytomegalovirus reinfections in healthy seroimmune women","volume":"201","author":"Ross","year":"2010","journal-title":"J Infect Dis"},{"key":"2026092314175747200_jiag170-B22","doi-asserted-by":"crossref","first-page":"12396","DOI":"10.1073\/pnas.1635160100","article-title":"Functional map of human cytomegalovirus AD169 defined by global mutational analysis","volume":"100","author":"Yu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092314175747200_jiag170-B23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1743-422X-6-4","article-title":"Feeling manipulated: cytomegalovirus immune manipulation","volume":"6","author":"Miller-Kittrell","year":"2009","journal-title":"Virol J"},{"key":"2026092314175747200_jiag170-B24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/infdis\/jiu215","article-title":"Postnatal acquisition of primary rhesus cytomegalovirus infection is associated with prolonged virus shedding and impaired CD4+ T lymphocyte function","volume":"210","author":"Antoine","year":"2014","journal-title":"J Infect Dis"},{"key":"2026092314175747200_jiag170-B25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coviro.2012.01.001","article-title":"Human cytomegalovirus entry into cells","volume":"2","author":"Vanarsdall","year":"2012","journal-title":"Curr Opin Virol"},{"key":"2026092314175747200_jiag170-B26","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fcimb.2020.00245","article-title":"Human cytomegalovirus interleukin 10 homologs: facing the immune system","volume":"10","author":"Poole","year":"2020","journal-title":"Front Cellular Infect Microbiol"},{"key":"2026092314175747200_jiag170-B27","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.136.12.4525","article-title":"Bacterial lipopolysaccharide-induced interferon-gamma production: roles of interleukin 1 and interleukin 2","volume":"136","author":"Le","year":"1986","journal-title":"J Immunol"},{"key":"2026092314175747200_jiag170-B28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coviro.2017.08.005","article-title":"Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections","volume":"25","author":"Itell","year":"2017","journal-title":"Curr Opin Virol"},{"key":"2026092314175747200_jiag170-B29","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1093\/infdis\/jiz484","article-title":"Animal models of congenital cytomegalovirus transmission: implications for vaccine development","volume":"221","author":"Roark","year":"2020","journal-title":"J Infect Dis"},{"key":"2026092314175747200_jiag170-B30","first-page":"25","article-title":"Seroepidemiologic studies of cytomegalovirus infection in a breeding population of rhesus macaques","volume":"44","author":"Vogel","year":"1994","journal-title":"Lab Anim Sci"},{"key":"2026092314175747200_jiag170-B31","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092314175747200_jiag170-B32","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/jiz447","article-title":"The status of vaccine development against the human cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J Infect Dis"},{"key":"2026092314175747200_jiag170-B33","doi-asserted-by":"crossref","first-page":"11323","DOI":"10.1128\/JVI.01925-13","article-title":"Vaccination against a virus-encoded cytokine significantly restricts viral challenge","volume":"87","author":"Eberhardt","year":"2013","journal-title":"J Virol"},{"key":"2026092314175747200_jiag170-B34","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1086\/322971","article-title":"Influence of maternal antibodies on neonatal immunization against respiratory viruses","volume":"33","author":"Crowe","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026092314175747200_jiag170-B35","doi-asserted-by":"crossref","first-page":"eabf3178","DOI":"10.1126\/sciadv.abf3178","article-title":"Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"key":"2026092314175747200_jiag170-B36","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092314175747200_jiag170-B37","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092314175747200_jiag170-B38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/infdis\/jiad593","article-title":"Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gB\/MF59 vaccine","volume":"230","author":"Hu","year":"2024","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag170\/67485053\/jiag170.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/e583\/67485053\/jiag170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/e583\/67485053\/jiag170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:18:07Z","timestamp":1790187487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/3\/e583\/8537868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag170","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,3,23]]}}}